Key statistics
On Monday, Longboard Pharmaceuticals Inc (LBPH:NMQ) closed at 59.91, -0.07% below its 52-week high of 59.95, set on Nov 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 59.83 |
---|---|
High | 59.95 |
Low | 59.80 |
Bid | 59.76 |
Offer | 59.94 |
Previous close | 59.80 |
Average volume | 859.10k |
---|---|
Shares outstanding | 39.05m |
Free float | 34.02m |
P/E (TTM) | -- |
Market cap | 2.33bn USD |
EPS (TTM) | -2.24 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
- Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
- Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
- Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
- Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
- Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
- Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
More ▼